Endocrine Toxicities of Antineoplastic Therapy
Open Access
Abstract
In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapyKeywords
This publication has 30 references indexed in Scilit:
- THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitorsEuropean Journal of Endocrinology, 2021
- Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinomaEndocrine, 2019
- Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitorsDrug Metabolism Reviews, 2019
- Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disordersCritical Reviews in Oncology/Hematology, 2019
- Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)Journal of Endocrinological Investigation, 2018
- Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitorsAnnales d'Endocrinologie, 2018
- Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusionsAnnales d'Endocrinologie, 2018
- Comprehensive analysis of the clinical immuno-oncology landscapeAnnals of Oncology, 2017
- Kinase Inhibitors: Adverse Effects Related to the Endocrine SystemThe Journal of Clinical Endocrinology & Metabolism, 2013
- Tyrosine Kinases as Targets for Cancer TherapyNew England Journal of Medicine, 2005